Stay updated with breaking news from க்ல் மூலதனம் குழு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Interim Results and Business Updates investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Centurium-led consortium completes $4.76b take-private deal of China Biologic April 22, 2021 Nasdaq-listed biopharmaceutical firm China Biologic Products Holdings suspended the trading of its shares on Wall Street on Wednesday, after the completion of a take-private deal sponsored by a Chinese buyout group that valued the firm at about $4.76 billion. The consortium is led by entities affiliated with Centurium Capital, a private equity (PE) firm founded by former Warburg Pincus partner David Li. Other investors in the consortium include Chinese PE company CITIC Capital; Asia-focused Hillhouse Capital; and V-Sciences Investments, a subsidiary of Singapore’s Temasek Holdings, among others. China Biologic signed the deal in November 2020, in which the investors had agreed to pay $120 per share in cash to privatise the firm through its merger with CBPO Group Limited. China Biologic will cease to be a publicly-traded company as a result of the deal. ....
Temasek leads $200m funding in Chinese dental services provider Arrail Group Photo: Bloomberg April 13, 2021 Beijing-based dental services provider Arrail Group has completed its Series E round funding, raising a corpus of nearly $200 million led by Singapore state investor Temasek Holdings, per a company statement on Tuesday. The latest funding saw participation from new investors OrbiMed Healthcare Fund Management, which manages about $13 billion in assets; Hong Kong-based asset management firm Ward Ferry Management (BVI) Limited; Korea’s Mirae Asset Group; and China’s Hina Group and Industrial Bank. CEC Capital, which invested in Arrail in 2014, served as the exclusive advisor for the deal. ....
SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange News provided by Share this article Share this article SHANGHAI, March 3, 2021 /PRNewswire/ SciClone Pharmaceuticals (Holdings) Limited ( SciClone Pharmaceuticals or SciClone ) was officially listed today on the Main Board of The Stock Exchange of Hong Kong Limited ( Hong Kong Stock Exchange or HKEx ) under stock code: 6600. In the initial offering, the 11,599,000 shares offered for subscription in the Hong Kong Public Offering was oversubscribed by 1,068.05 times. The Offer Price was HK$18.80 per Offer Share, and the Global Offering has raised a total amount of HK$2,039.5 million in net proceeds (after deducting underwriting fees and commissions paid and payable in connection with the global offering and estimated expenses and assuming the Over-allotment Option is not exercised). ....
SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.